LUNAI BIOWORKS INC (RENB) Fundamental Analysis & Valuation

NASDAQ:RENB • US29350E1047

Current stock price

1.42 USD
+0.15 (+12.16%)
At close:
1.54 USD
+0.12 (+8.45%)
After Hours:

This RENB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RENB Profitability Analysis

1.1 Basic Checks

  • In the past year RENB has reported negative net income.
  • In the past year RENB has reported a negative cash flow from operations.
  • In the past 5 years RENB always reported negative net income.
  • RENB had a negative operating cash flow in each of the past 5 years.
RENB Yearly Net Income VS EBIT VS OCF VS FCFRENB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • RENB's Return On Assets of -57.15% is in line compared to the rest of the industry. RENB outperforms 45.44% of its industry peers.
  • RENB has a Return On Equity (-76.11%) which is in line with its industry peers.
Industry RankSector Rank
ROA -57.15%
ROE -76.11%
ROIC N/A
ROA(3y)-83.86%
ROA(5y)-54.42%
ROE(3y)-100.89%
ROE(5y)-64.97%
ROIC(3y)N/A
ROIC(5y)N/A
RENB Yearly ROA, ROE, ROICRENB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

  • RENB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RENB Yearly Profit, Operating, Gross MarginsRENB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. RENB Health Analysis

2.1 Basic Checks

  • RENB has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RENB has more shares outstanding
  • The debt/assets ratio for RENB has been reduced compared to a year ago.
RENB Yearly Shares OutstandingRENB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
RENB Yearly Total Debt VS Total AssetsRENB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of 1.34, we must say that RENB is in the distress zone and has some risk of bankruptcy.
  • RENB has a better Altman-Z score (1.34) than 62.94% of its industry peers.
  • There is no outstanding debt for RENB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACCN/A
RENB Yearly LT Debt VS Equity VS FCFRENB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 0.13 indicates that RENB may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.13, RENB is doing worse than 96.46% of the companies in the same industry.
  • A Quick Ratio of 0.13 indicates that RENB may have some problems paying its short term obligations.
  • The Quick ratio of RENB (0.13) is worse than 96.28% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
RENB Yearly Current Assets VS Current LiabilitesRENB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. RENB Growth Analysis

3.1 Past

  • RENB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.96%, which is quite impressive.
EPS 1Y (TTM)59.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RENB Yearly Revenue VS EstimatesRENB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 0 0 0 0 0

More info and screens

Find the best growth stocksShow best growing peers

0

4. RENB Valuation Analysis

4.1 Price/Earnings Ratio

  • RENB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RENB Price Earnings VS Forward Price EarningsRENB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RENB Per share dataRENB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RENB Dividend Analysis

5.1 Amount

  • No dividends for RENB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RENB Fundamentals: All Metrics, Ratios and Statistics

LUNAI BIOWORKS INC

NASDAQ:RENB (9/30/2025, 8:00:02 PM)

After market: 1.54 +0.12 (+8.45%)

1.42

+0.15 (+12.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-29
Earnings (Next)11-12
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap327.92M
Revenue(TTM)N/A
Net Income(TTM)-67.28M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.71
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS0.38
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -57.15%
ROE -76.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.86%
ROA(5y)-54.42%
ROE(3y)-100.89%
ROE(5y)-64.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 1.34
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)31.12%
Cap/Depr(5y)59.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.3%
OCF growth 3YN/A
OCF growth 5YN/A

LUNAI BIOWORKS INC / RENB Fundamental Analysis FAQ

What is the fundamental rating for RENB stock?

ChartMill assigns a fundamental rating of 1 / 10 to RENB.


Can you provide the valuation status for LUNAI BIOWORKS INC?

ChartMill assigns a valuation rating of 0 / 10 to LUNAI BIOWORKS INC (RENB). This can be considered as Overvalued.


Can you provide the profitability details for LUNAI BIOWORKS INC?

LUNAI BIOWORKS INC (RENB) has a profitability rating of 1 / 10.


Can you provide the financial health for RENB stock?

The financial health rating of LUNAI BIOWORKS INC (RENB) is 4 / 10.